Contents

Search

Australian enalapril hypertension study

Open label, randomized trial, supported by the Australian government & the makers of enalapril. 6083 hypertensive patients, age 65-84 almost all patients white patients healthy: - few patients had diabetes or known coronary artery disease mean blood pressure 168/91 ACE inhibitor or diuretic as initial therapy - Enalapril & HCTZ were recommended, but were not mandatory - Additional medication administered with monotherapy was inadequate 4 years of follow-up Results: 1) blood pressure reduction identical in both groups 2) combined endpoint of cardiovascular event or all-cause mortality 5.6% in ACE inhibitor group, 6.0% in diuretic group (p=0.05) 3) ACE inhibitor group had significantly lower rate of myocardial infarction, but not stroke or all-cause mortality

General

hypertension clinical trials

References

  1. Journal Watch 23(6):45, 2003 Wing LMH et al, N Engl J Med 348:583, 2003 Frohlich ED,N Engl J Med 348:639, 2003 August P, N Engl J Med 348:610, 2003
  2. Prescriber's Letter 10(4):19 2003